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THE ROLE OF POST GRANULOCYTE COLONY-STIMULATING FACTOR
WHITE BLOOD CELL COUNTS IN PREDICTING THE MOBILIZATION AD-
VERSE EVENTS AND YIELDS
Wang, T.-F.1,2, Chen, S.-H.2,3, Chang, C.-Y.2, Yang, S.-H.2,3, Su, Y.-
C.4, Chu, S.-C.1, Yang, K.-L.2 1Buddhist Tzu-Chi General Hospital,
Hualien, Taiwan; 2Buddhist Tzu-Chi Stem Cell Center, Hualien,
Taiwan; 3Buddhist Tzu-Chi General Hospital, Hualien, Taiwan;
4Buddhist Tzu-Chi General Hospital, Cha-Yi, Taiwan
Background: To evaluate the incidences of adverse events of gran-
ulocyte colony-stimulating factor (G-CSF) and the impacts of post
G-CSF white blood cell (WBC) counts on adverse events and mobi-
lization yields in healthy peripheral blood stem cell donors.
Materials and Methods: Four hundred seventy-six healthy donors
were given G-CSF of 10mg/kg/day for 5-6 consecutive days. The
WBC counts were determinated at baseline, after third dose (before
the forth dose on Day4) and after fifth dose (before leukapheresis on
Day5) of G-CSF administration. Performance status and symptoms
were recorded everyday beforeG-CSF injection. The incidences of ad-
verse events and mobilization yields were compared between different
donor characteristic groups. Multivariate analysis was used to analyze
the correlations between the adverse events and donor factors.
Results: Bone pain (64.9%), myalgia/arthralgia (58.2%), fatigue
(44.1%) and headache (33.0%) were the most common side effects.
The third day and fifth day median WBC counts were 35,050/mL
and 45,905/mL. Donors with WBC $ 50x103/mL after 3 doses of
G-CSF experienced more fatigue, myalgia/arthralgia and chills (p
5 0.0314, 0.0066 and 0.0121) but post G-CSF CD34+ cells were
similar (72.6/mL vs 68.7/mL, p 5 0.5916). Although the CD34+ cells
were higher in donors with WBC $ 50x103/mL after 5 doses of G-
CSF (89.3/mL vs 59.1/mL, p\0.0001), the incidences of side effects
were similar. Female donors more frequently had headache, nausea/
anorexia, vomiting, fever (p 5 0.003,\ 0.0001, 0.0016 and 0.0392)
and lower post G-CSF CD34+ cell count than male donors did
(78.0/mL vs 59.0/mL, p\ 0.0001). Donors with body mass index $
25 had higher incidences of sweat and insomnia (p 5 0.0211 and
0.0318) and also higher CD34+ cell count (79.9/mL vs 64.9/mL, p
\ 0.0001). Donor receiving G-CSF $ 10mg/kg tended to have
bone pain, headache and chills (p 5 0.0085, 0.0270 and 0.0085).
The side effects and CD34+ cells were not different between young
and old donors.
In multivariate analysis, female donor experienced more fatigue,
nausea, vomiting, bone pain, myalgia/arthragia, headache, fever
and insomnia. Higher BMI donor had more fatigue, myalgia/arthra-
gia and sweats. G-CSF dose was associated with bone pain and the
WBC count post the third G-CSF was associated with fatigue only.
Conclusion: Female and high BMI donors are associated with
higher risk of side effects of PBSC mobilization by G-CSF. Routine
monitor of the post G-CSF WBC count provide minimal benefit in
predicting side effects. Reducing dose or discontinuation of G-CSF
should mainly base on the clinical severity of adverse events.
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AFFECT OF CARDIAC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FROM VARIOUS STEM CELL
SOURCES
Nishinohara, M., Kobayashi, K., Maeda, Y., Shinagawa, K.,
Tanimoto, M. Okayama University Hospital, Okayama, Okayama, Japan
Background: Cardiac complications after Allogenic Hematopoietic
Stem Cell Transplantation (allo-SCT) have varied among studies.
Furthermore, various stem cell sources have increasingly been used
as a therapeutic option, it remains unknown the affect of cardiac
complications after allo-SCT from various stem cell sources.
Patients and Methods: We retrospectively reviewed 172 patients
underwent allo-SCT at Okayama University Hospital between
May 2004 and October 2010, for whom electrocardiography
(ECG) and ultrasound cardiography (UCG) within 3 months before
transplantation. The median age at allo-SCT was 50 years (range:
16-74). Donor sources were related peripheral blood in 41, related
bone marrow in 13 and unrelated bone marrow in 66, and umbilical
cord blood in 52 cases, respectively. 80 (46.5%) patients had high risk
disease at the time of transplantation.Results:We identified 31 patients (18%) with grade 2-4 cardiac com-
plications within 28 days after allo-SCT according to the Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). 4 patients
(0.02%) developed grade 3-4 cardiac complications. The median
time of onset after allo-SCT was 9 days (range: -7-23 days). Manifes-
tation of cardiac complications was mainly pulmonary congestion in
19, while hypertension in 5, arrhythmia in 3, pericardial effusion in
2, cardiac ischemia in 1 and hypotension in 1 case, respectively. 2 pa-
tients died of cardiac causes after the onset of severe cardiac complica-
tions. The cumulative 1-year overall survival in patients with or
without cardiac complication was 46.8% and 57.2%, respectively (p
5 0.29). There was no difference in the ECG/UCG findings, the cu-
mulative dose of anthracyclines and between patients with and without
cardiac complications. Furthermore, no difference in rate of cardiac
complications was observed in among stem cell sources.
Conclusion: Although from a retrospective study, these results sug-
gest that cardiac complications were associated with relatively poor
survival but not with stem cell sources although this finding must
be considered with caution due to the small sample size.
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LINEAGE-SPECIFIC CHIMERISM ANALYSIS IS A SENSITIVE PREDICTOR OF
OUTCOME AFTER ALLOGENEIC MYELOABLATIVE AND NONMYELOABLA-
TIVE STEM CELL TRANSPLANTATION
Saracino, G.1,2, Agura, E.1,2,3, Berryman, B.1,2,3, Fay, J.1,2,3,
Pineiro, L.1,2,3, Vance, E.1,2,3, Saad, R.1 1Baylor University Medical Cen-
ter, Dallas, TX; 2Charles A. Sammons Cancer Center, Dallas, TX;
3Texas Oncology PA, Dallas, TX
Monitoring chimerism in allogeneic hematopoietic stem cell
transplant (HSCT) recipients is of great clinical significance after
different conditioning regimens. Analysis of lineage-specific leuko-
cytes provides useful information in predicting the clinical outcome
and plays a critical role in the management of HSCT patient. We
have analyzed donor-type chimerism in CD3+ T cells, CD19+ B
cells, CD15 + myeloid cells and CD34+ progenitor cells in patients
who had undergone myeloablative and nonmyeloablative HSCT
for acute myeloid leukemia (AML) and non-AML. The engraftment
analysis was performed by PCR-based detection of donor- and recip-
ient-specific short tandem repeats (STR) using enriched T cells, my-
eloid cells, B cells and progenitor cells from peripheral blood and
bonemarrow samples prior to isolation of DNA. Chimerism analysis
performed onCD34+ progenitor cells wasmost useful in early detec-
tion of relapse in AML patients than unfractionated whole blood
analysis due the increased sensitivity in the enriched cell subpopula-
tions. Monitoring of leukemia- and lymphoma-affected cell lineage
predicted relapse. Determination of the level of donor T cells ap-
pears to be critical for successful engraftment and predict graft versus
host disease in transplant patients who underwent nonmyeloablative
HSCT. Donor-type chimerism in lineage-specific cell population
appears to impact outcome and allows early intervention.
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SAFETY OF LIPOSOMAL AMPHOTERICIN B IN ALLOGENIC HEMATOPOI-
ETIC TRANSPLANTATION (HSCT) RECIPIENTS
Nakano, N.1, Nishida, A.1, Ohota, H.1, Ikebe, T.1, Shimazu, H.1,
Ishiwata, K.1, Araoka, H.2, Tsuji, M.1, Yamamoto, H.1, Asano-
Mori, Y.1, Izutsu, K.1, Uchida, N.1, Yoneyama, A.2, Wake, A.3,
Makino, S.4, Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan;
2Toranomon Hospital, Tokyo, Japan; 3Toranomon Hospital Kajigaya,
Kawasaki, Japan; 4Toranomon Hospital, Tokyo, Japan
In the patients performed HSCT, liposomal amphotericin B (L-
AMB) is one of useful antifungal agents because of its broad-spec-
trum. However, little was known about the safety of L-AMB in
allogenic HSCT setting. There were 90 patients administrated L-
AMB around allogenic HSCT in our institute from December
2007 to November 2009 consecutively. Thirty-two of those 90 pa-
tients were administrated L-AMB at least for 1 week during in day
-30 to 120 after HSCT. We analyzed those 32 patients, included
23 males and 9 females, retrospectively. Median age was 58 (29-68)
yrs. Stem cell sources of HSCT were 22 CB, 7 unrelated BM and
3 sibling-PB respectively. Two patients used L-AMB as prevention
to invasive fungal infections (IFIs) and 30 treatment. Thirty-one pa-
tients received other prior anti-fungal therapies. Median follow up
period from the day starting L-AMB was 71.5 (7-466) days. Median
Poster Session II S321time to start L-AMB from HSCT was day 9 (day-34 - day103), and
median duration of usage was 23 (7-151) days. Median time to accel-
erated point (over normal range) and maximum point of serum
creatinine level from the day of starting administration were 6 and
12 (1-29 and 3-73) days respectively. Maximum creatinine level
was significantly higher in patients using for over 23 days compared
with that of shorter. Median replacement dose of potassium and
magnesium were 55 (0-160) mEq/day and 20 (0-35) mEq/day re-
spectively. Median starting dose of L-AMB was 2.5 (2-5) mg/kg.
Breakthrough fungal infections were detected in one patient with
Candida glabrata, one patients with probable aspergillosis and two
probable other fungal infection. All patients were administrated in
combination with several drugs including immune suppressants,
vancomycin. In conclusion, although feasible usage of LAMB, it
should be paid attention to nephrotoxicity especially due to long-
term usage, hypokalemia, kypomagnesemia and breakthrough IFIs
in allogenic HSCT recipients using L-AMB.
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STANDARDIZATION OF CD34 TESTING IS NEEDED FOR PHERESIS PROCE-
DURE DETERMINATION
Fortney, C.A., McKinnon, R., Carey, J., Janakiraman, N. Henry Ford
Hospital, Detroit, MI
Flow Cytometric enumeration of CD34+ and Hematopoietic
StemCells is widely used for determining the adequacy of collection.
Though most centers use ISHAGE approved platforms, there are
wide variations in results affecting the number of collections done.
Variables that could possibly affect these results may include: sample
dexterity influenced by travel time which can increase background
staining of antibody, variations in Flow Cytometry processing
method, Flow Cytometer equipment, gating methods, and skill set
of those completing the testing. CD34 results can affect the determi-
nation by a DC to stop pheresis collections.
We looked at results of 21 products from unrelated donors
received at our Transplant Center (TC) and compared our CD34 re-
sults against the Donor Center’s (DC) CD34 results. Our TC center
CD34 values ranged from 1.90 – 44.60 x 106 CD34/kg of recipient
weight (median 5.33), The DC CD34 values ranged from 3.11 –
20.47 x 106 CD34/kg (median 8.5). In total, 90% of the TC CD34
values were less than the DC results with a range of 21%-417% (me-
dian 61.5%). Product travel time was looked at to determine if it may
have affected the difference in CD34 results. Approximate time be-
tween testing at DC and testing at TC ranged from 6 – 47 hours (me-
dian 34.625). No correlation was found between approximate
elapsed time of sample testing and CD34 results. CD34 values had
no effect on patient engraftment (ANC 500 range 7-25 days, median
15d; Plt 20 range 14-69 days, median 20d).
In summary, there is a wide variation in the estimated number of
CD34+ cells in the product between the DC and TC. The possible
explanations are discussed above. It is not clinically significant in
our group since the number of cells infused is still much higher
than the minimum required for engraftment.
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL RECIPIENTS
DIAGNOSED WITH INVASIVE FUNGAL INFECTION PRIOR TO TRANS-
PLANT PROCEDURE
Gorczynska, E.1, Kalwak, K.1, Owoc-Lempacj, J.1, Janczak, K.1,
Dorobisz, T.1, Kulej, D.1, Ussowicz, M.1, Mielcarek, M.1, Dyla, A.1,
Chybicka, A.1, Musial, J.1, Nawrot, U.2 1Medical University of Wroclaw,
Wroclaw, Poland; 2Medical University of Wroclaw, Wroclaw, Poland
The mortality of allogeneic hematopoietic stem cell (allo-HSC)
recipients transplanted with invasive fungal infection (IFI) is high
due to the risk of infection progression. Eleven (8 children and 3
adults) out of 256 (4.3%) patients who underwent allo-HSCT
from January 2005 to August 2010 at Wroclaw Pediatric Transplant
Center were diagnosed with IFI, classified as possible (4), probable
(2) or proven (5), median 40 days (11 - 60) prior to allo-HSCT. In
spite of persistent IFI, transplant procedures were not postponed
due to advanced underlying diseases: acute leukemias in unstable re-
mission (10) or aplastic anemia (1). Two patients (1 Rhisopus dissem-
inated infection, 1 probable lung Aspergillosis) died of lung
insufficiency (septic shock or capillary leak syndrome) before en-
graftment. Both received combined antifungal treatment: amphoter-icin lipid complex (ABLC) or liposomal formulation (L-AMB) +
posaconazole (PCZ) or echinocandine. One patient with proven As-
pergillosis treated with ABLC followed by Posa died of a leukemia
relapse 1 year post allo-HSCT without symptoms of IFI. Eight pa-
tients with previous lung infection are alive for median 17,6 months
(2 - 69. 5) post allo-HSCT. Complete resolution of lung infiltrates
was achieved in 6 and partial in one (still on treatment). In 5 of
them several antifungal drugs (VCZ, PCZ, LAMB, echinocandins)
were used in different sequences as monotherapy (switched one to
other according to treatment response or toxicity). Two patients re-
ceived combined therapy with echinocandine + VCZ or ABLC. In-
tensive antifungal treatment was followed by secondary
prophylaxis with itraconazole (3), PCZ (2) or VCZ (2) for median
6 months (2-22). Three out of 7 patients underwent resection of per-
sistent pulmonary lesions. One patient with possible lung Aspergil-
losis was treated with L-AMB switched to VCZ followed by PCZ
until 13 months post HSCT which resulted in resolution of lung le-
sions reappearing one month later Then antifungal therapy was
given again (VCZ followed by PCZ) for 10 months. Five years after
allo-HSCT and 2.5 years off antifungal treatment, he is well, how-
ever CT imaging revealed new lung infiltrates.
Conclusions: Active IFI is not a contraindication for allo-HSCT.
IFI treatment has to be intensive and include secondary prophylaxis
with anti-mold effective drugs. In case of insufficient response to an-
tifungal monotherapy both combination treatment and surgical
intervention may be used as salvage option.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE
MYELOID LEUKEMIA – THE RETROSPECTIVE ANALYSIS
Vondrakova, J.1, Belohlavkova, P.2, Zapletalova, J.3, Raida, L.1, Zak, P.2,
Jebavy, L.2, Voglova, J.2, Zavrelova, A.2, Pikalova, Z.1, Skoumalova, I.1,
Jarosova, M.1, Faber, E.1, Maly, J.2, Indrak, K.1 1University Hospital,
Olomouc, Czech Republic; 2University Hospital, Hradec Kralove, Czech
Republic; 3Medical Faculty, Palacky University, Olomouc, Czech Republic
Background: Myelodysplastic syndromes (MDS) are the heteroge-
nous group of diseases with a different risk of development to acute
leukemia (AL). The allogeneic stem cell transplantation (alloSCT) is
one of the treatment possibilities that is more accessible thanks to
availability of recent conditioning regimes. Many questions are still
open. The goal of the retrospective analysis was the evaluation of al-
loSCTs performed in two transplantation centres to estimate the im-
portance of alloSCT for MDS patients (pts), to evaluate prognostic
parametres and the course of alloSCTs and overall survival (OS). Pa-
tients characteristics: The cohort consisted of 30 pts, male:female ra-
tio was 1:1, transplanted in 1997 – 2010, the age were 23 – 63 year
(median 56). According the WHO 2001 classification the pts were
initially classified as: 2 (7%) 5q- sy, 2 (7%) RARS, 9 (30%)
RCMD, 6 (20%) RAEB I, 11 (36%) RAEB II, according to IPSS
as: 2 (6%) low risk, 11 (37%) intermediate-1, 11 (37%) intermedi-
ate-2, 6 (20%) high risk. In 13 cases (43%) alloSCT was performed
in leukemic phase, in majority of cases after induction/consolidation
chemotherapy. 6 (20%) pts underwent alloSCT during the progres-
sion into more advanced MDS and 11 (37%) in phase of stabile dis-
ease. 11 pts (37%) underwent myeloablative conditioning regime
and 19 (63%) pts reduced intensity regime. 14 transplantations
were from sibling donors, 16x from unrelated donors, only in 1
case was used bone marrow.
Results: Median of follow-up from MDS diagnosis was 33 months,
from alloSCT 15 months. Transplantation was performed in median
of 11 months from diagnosis of MDS. 11 pts died in the whole cohort
– the reasonwas the progressionof disease (4x), infection complications
(4x), GVHDand current infection (3x). It dealt initially about themost
riskyMDS,8 (27%) transformed intoAL, accordingIPSS4 (13%)were
initially high risk, 7 (23%) intermediate (int-1 and int-2).Median from
diagnosis was 12 and from alloSCT 3months. Other pts have received
long time remission and in the low risk MDS transfusion dependence
was removed and the quality of life was outstandingly improved. At
the moment 19 (63%) pts live with median of follow-up 49 month
fromMDS diagnosis and 27 months from alloSCT.
Conclusion: It is possible curatively influence MDS or secondary
AL in favour of patient exploiting aloSCT. Consideration of this cu-
rative possibility should have become routine part of diagnostic-
prognostic algorithm in MDS patients.
